P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY

J.-Z. Hou, N. G. Daver, D. A. Stevens, T. Yamauchi, Y. Moshe, C. Y. Fong, A. Marzocchetti, R. Adamec, M. Patel, S. Lambert, K. Y. Wu, C. Röllig

Open source

DOI: 10.1097/01.hs9.0000845136.98578.78
Published: 2022-06
Container: HemaSphere
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000845136.98578.78,
  title = {P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY},
  author = {J.-Z. Hou and N. G. Daver and D. A. Stevens and T. Yamauchi and Y. Moshe and C. Y. Fong and A. Marzocchetti and R. Adamec and M. Patel and S. Lambert and K. Y. Wu and C. Röllig},
  year = {2022},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000845136.98578.78},
  url = {https://doi.org/10.1097/01.hs9.0000845136.98578.78}
}

RIS

TY  - JOUR
TI  - P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
AU  - J.-Z. Hou
AU  - N. G. Daver
AU  - D. A. Stevens
AU  - T. Yamauchi
AU  - Y. Moshe
AU  - C. Y. Fong
AU  - A. Marzocchetti
AU  - R. Adamec
AU  - M. Patel
AU  - S. Lambert
AU  - K. Y. Wu
AU  - C. Röllig
PY  - 2022
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000845136.98578.78
UR  - https://doi.org/10.1097/01.hs9.0000845136.98578.78
ER  -

APA

Hou, J., Daver, N. G., Stevens, D. A., Yamauchi, T., Moshe, Y., Fong, C. Y., Marzocchetti, A., Adamec, R., Patel, M., Lambert, S., Wu, K. Y., & Röllig, C. (2022). P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY. HemaSphere. https://doi.org/10.1097/01.hs9.0000845136.98578.78

Source records

crossref · retrieved 2026-09-25T22:19:42.633Z